Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals — Q3 2024 Earnings Presentation

38 slides from Day One Biopharmaceuticals's earnings presentation, Oct 30, 2024

  1. Slide 1: Targeted Therapies for People of All Ages

    Day One Biopharmaceuticals Targeted Therapies for People of All Ages October 2024

  2. Slide 2: Disclaimer

    Disclaimer This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and uncertainties, some

  3. Slide 3: Cancer Therapies for People of All Ages

    Cancer Therapies for People of All Ages Develop medicines for genomically-defined cancers Establish first-in-class position through rapid registration pathways Expand to adolescent and adult populations in parallel and pursue those opportunities with the same commitment we do for children Our Approa

  4. Slide 4: Our Pipeline

    1 OJEMDA has received accelerated approval by the U.S. Food and Drug Administration. 2 FIREFLY-1 is an open-label, pivotal Phase 2 trial. 3Ex-U.S. license agreement with Ipsen to commercialize OJEMDA (tovorafenib) outside the U.S. DAY301 is a license agreement with MabCare Therapeutics for exclusive

  5. Slide 5: OJEMDA (tovorafenib) Relapsed or Refractory BRAF-altered pLGG

    OJEMDATM (tovorafenib) Relapsed or Refractory BRAF-altered pLGG

  6. Slide 6: Pediatric Low-Grade Glioma: The Most Common Type Of Brain Tumor In Children

    Pediatric Low-Grade Glioma: The Most Common Type Of Brain Tumor In Children pLGGs are chronic and relentless, with patients suffering profound tumor and treatment-associated morbidity that can impact their life trajectory over the long term1 A Serious and Life-Threatening Disease For the majority of

  7. Slide 7: Sources

    Source: 1. Heitzer AM, Raghubar K, Ris MD, et al. Neuropsychological functioning following surgery for pediatric low-grade glioma: a prospective longitudinal study. J Neurosurg Pediatr. 2019;1-9. doi:10.3171/2019.9.PEDS19357. 2. Bryant R. Managing side effects of childhood cancer treatment. J Pediat

  8. Slide 8: Overview U.S. Prescribing Information For OJEMDA

    Overview U.S. Prescribing Information For OJEMDATM (tovorafenib) *This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial. INDICATION

  9. Slide 9: Efficacy Summary From OJEMDA Prescribing Information

    Efficacy Summary From OJEMDATM (tovorafenib) Prescribing Information Overall response rate (RAPNO-LGG) in 76 evaluable patients 51% Response (IRC) RAPNO-LGG n n (%) 95% CI ORR, n (%) BRAF fusion or rearrangement BRAF V600 mutation Prior MAPKi use MAPKi-naïve Median DOR, months Median TTR, months Ran

  10. Slide 10: Safety Summary From OJEMDA Prescribing Information

    Warnings and Precautions Hemorrhage Skin toxicity, including photosensitivity Hepatotoxicity Effect on growth Embryo-fetal toxicity Use in NF1- associated tumors Safety Summary From OJEMDATM (tovorafenib) Prescribing Information No boxed warnings or contraindications TEAEs (≥ 30% of patients [n=137]

  11. Slide 11: Addressable U.S. Opportunity of OJEMDA

    Addressable U.S. Opportunity of OJEMDA Estimated to be ~2,000-3,000 Patients Incident Therapeutic Build for New pLGG Patients to be Treated in Frontline Setting U.S. Incident Patients <25 years old with CNS Tumors (0.00521%)1,2 ~5,500 Rate of Low Grade Gliomas (Gliomas rate 63%, Low-Grade 77%)2 ~2,6

  12. Slide 12: Product Profile Aligns With What Physicians Are Looking For

    Product Profile Aligns With What Physicians Are Looking For In A Therapy Data from Pivotal Phase 2 FIREFLY-1 trial. Meaningful tumor stabilization or shrinkage may be possible with OJEMDA. In the clinical trial: 51% of children experienced tumor shrinkage by at least 25% 82% of children saw their tu

  13. Slide 13: Strong Q3 Patient Demand Continues to Drive Performance

    Strong Q3 Patient Demand Continues to Drive Performance HCP, Health Care Professional. * Total prescriptions includes prescriptions for all patients (new & refill, paid & free drug and on-label & off-label patients), prescriptions are approximations based on data available on September 30, 2024. Str

  14. Slide 14: Coverage Approval Rates are High Across Commercial and Medicaid Payers

    Coverage Approval Rates are High Across both Commercial and Medicaid Payers Despite Limited Published Coverage Reported Coverage1,2 Percent of Covered Lives 1 Breakaway Partners LLC – Breakaway Partners Analytics Platform. Metrics Based on 190.5M Commercial Lives . 2 Artia Solutions - Medicaid Cover

  15. Slide 15: Well-Positioned For Commercial Execution And Sustained Growth

    Well-Positioned For Commercial Execution And Sustained Growth Continuing Launch Trajectory Increase breadth & depth of prescribers Position OJEMDA as the standard of care in 2nd line Establish remaining payer coverage policies

  16. Slide 16: FIREFLY-2 / LOGGIC Pivotal Phase Trial of Tovorafenib in Frontline pLGG

    FIREFLY-2 / LOGGIC Pivotal Phase 3 Trial of Tovorafenib in Frontline pLGG

  17. Slide 17: FIREFLY-2/LOGGIC Trial Design

    FIREFLY-2/LOGGIC Pivotal Phase 3 Trial Of Tovorafenib In Frontline pLGG Trial Design * COG or SIOPe-LGG regimen. Abbreviations: CHG, chiasmatic, hypothalamic glioma; DoR, duration of response; LGG, low-grade glioma; ORR, objective response rate; QoL, quality of life; QW, once weekly; SoC, standard o

  18. Slide 18: DAY301 PTK7 Targeted Antibody Drug Conjugate

    DAY301 PTK7 Targeted Antibody Drug Conjugate (ADC)

  19. Slide 19: DAY301: Next Generation ADC Targeting PTK7

    DAY301: Next Generation ADC Targeting PTK7 1 Cho BC, et al. Ann Oncol. (34; Suppl 2): S460-S461, 2023. PTK7: Clinically-Validated ADC Target DAY301: Potential First-in-Class Asset Substantial Development and Commercial Opportunities for DAY301 Anti-tumor activity of anti-PTK7 ADC demonstrated in Pha

  20. Slide 20: PTK7: A Clinically-Validated ADC Target

    PTK7: A Clinically-Validated ADC Target 1 Phase 1b study of PF-06647020/ABBV-647. Potential opportunity for a next-generation PTK7 ADC with improved therapeutic index Clinical results for cofetuzumab pelidotin1 demonstrated proof of concept for PTK7-targeted ADCs Cofetuzumab pelidotin activity seen

  21. Slide 21: DAY301: Potential First-In-Class Asset

    DAY301: Potential First-In-Class Asset 1) Damelin M, et al. A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions. Sci Transl Med. 2017. HNSTD, Highest Non-Severely Toxic Dose; P-gp, P-glycoprotein. DAY301 has been designed to maximize therape

  22. Slide 22: DAY301: First-in-Class Potential

    DAY301: First-in-Class Potential PDX 362310 TNBC H-score 255 PDX 362797 SCLC H-score 210 PDX LD1-200615 HNSCC H-score 120 0 1,000 2,000 3,000 0 20 40 60 80 Tumor Volume (mm3) (Mean ± SEM) Days Post Administration 0 1,000 2,000 3,000 4,000 0 7 14 21 28 Tumor Volume (mm3) (Mean ± SEM) Days Post Admini

  23. Slide 23: DAY301: Encouraging Development And Commercial Opportunities

    DAY301: Encouraging Development And Commercial Opportunities Indication PTK7 Expression (>1+) U.S. Patient Population Cases/deaths ORR at Relapse Median OS at Relapse Endometrial 100%2 67,880/13,2503 39%7 9 months7 Esophageal SCC​ 76%1 22,370/16,1303 5%4 3 months4 Gastric 35%2 26,890/10,8803 12%14 6

  24. Slide 24: DAY301-001: Initial Phase 1a/b Clinical Trial Design

    DAY301-001: Initial Phase 1a/b Clinical Trial Design DL, Dose Level; RD, Recommended Dose; BOIN, Bayesian Optimal Interval; HNSCC, Head and Neck Squamous Cell Carcinoma; SCLC, Small Cell Lung Cancer; SCC, Squamous-Cell Carcinoma; NSCLC, Non-Small Cell Lung Cancer Phase 1a: Monotherapy Dose Escalatio

  25. Slide 25: Summary

    Summary

  26. Slide 26: Third Quarter 2024 Financial Results

    Third Quarter 2024 Financial Results All financial information is unaudited. 1 Includes stock-based compensation expense of $3.8 million and $13.2 million for the three and nine months ended 9/30/24, and $3.3 million and $10.1 million for the three and nine months ended 9/30/23, respectively. 2 Incl

  27. Slide 27: Priorities as a Commercial-Stage Company

    Priorities as a Commercial-Stage Company Expand awareness amongst physicians and establish broad coverage to enable patient access Establish OJEMDA as the standard of care for relapsed or refractory pLGG harboring a BRAF alteration Provide a positive and supportive experience when initiating OJEMDA

  28. Slide 28: Appendix

    x Append Day One 28

  29. Slide 29: Tovorafenib Inhibits Both BRAF Fusions And BRAF V600 Mutations

    Tovorafenib Inhibits Both BRAF Fusions And BRAF V600 Mutations Tovorafenib is an investigational, oral, selective, CNS-penetrant, type II RAF inhibitor that was designed to inhibit both monomeric and dimeric RAF kinase Activity in tumors driven by both RAF fusions and BRAF V600E mutations Tablet and

  30. Slide 30: Pivotal Phase 2 Trial Of Monotherapy Tovorafenib (FIREFLY-1)

    June 5, 2023 data cutoff. 1 Wen PY, et al. J Clin Oncol. 2010;28(11):1963-1972. 2 Fangusaro J, et al. Lancet Oncol. 2020;21(6):e305–316. 3 van den Bent MJ, et al. Lancet Oncol. 2011;12(6):583-593. Abbreviations: CBR, clinical benefit rate; IRC, independent review committee; C, cycle; D, day; LGG, lo

  31. Slide 31: Data from Pivotal Phase FIREFLY-1 Trial

    Data from Pivotal Phase 2 FIREFLY-1 Trial June 5, 2023 data cutoff

  32. Slide 32: FIREFLY-1 Baseline Patient Characteristics

    FIREFLY-1 Baseline Patient Characteristics June 5, 2023 data cutoff. *Includes 6 patients with BRAF duplication and 2 with BRAF rearrangement per fluorescence in situ hybridization or in situ hybridization. †Includes tumors that were extending into multiple regions of the brain, leptomeningeal disea

  33. Slide 33: Tumor Response To Tovorafenib Using RAPNO-LGG, RANO-LGG and RANO-HGG

    Tumor Response To Tovorafenib Using RAPNO-LGG, RANO-LGG and RANO-HGG Maximum change in tumor size (%) Maximum change in tumor size (%) Maximum change in tumor size (%) RAPNO-LGG RANO-LGG RANO-HGG June 5, 2023 data cutoff. BOR, best overall response; CBR, clinical benefit rate; CI, confidence interva

  34. Slide 34: Duration Of Tovorafenib Therapy: RAPNO-LGG Evaluable Lesions

    Duration Of Tovorafenib Therapy For All Patients With RAPNO-LGG Evaluable Lesions June 5, 2023 data cutoff. Patients Overall treatment duration (months) 5.3 Months 13.8 Months Median time to response Median duration of treatment

  35. Slide 35: Duration Of Tovorafenib Therapy: RANO-HGG Evaluable Lesions

    Duration Of Tovorafenib Therapy For All Patients With RANO-HGG Evaluable Lesions Patients Overall treatment duration (months) June 5, 2023 data cutoff. 3.0 Months 16.6 Months Median time to response Median duration of treatment

  36. Slide 36: Duration Of Tovorafenib Therapy: RANO-LGG Evaluable Lesions

    Duration Of Tovorafenib Therapy For All Patients With RANO-LGG Evaluable Lesions Patients Overall treatment duration (months) June 5, 2023 data cutoff. 5.5 Months 14.4 Months Median time to response Median duration of treatment

  37. Slide 37: Tumor Response Across Three Assessment Criteria

    Tumor Response To Tovorafenib Across Three Assessment Criteria Were Consistent Across BRAF Fusion And Mutation Patients, and Patients With Prior MAPK Treatment June 5, 2023 data cutoff. 1 Fangusaro J, et al. Lancet Oncol. 2020;21(6):e305–316. 2 Fangusaro J, et al. Lancet Oncol. 2020;21(6):e305–316.

  38. Slide 38: Tovorafenib Safety Data (n=137)

    Tovorafenib Safety Data (n=137) June 5, 2023 data cutoff. Treatment-emergent AEs ≥25% any grade in arms 1 & 2. AE, adverse event; ALT, Alanine transaminase; AST, aspartate aminotransferase; COVID-19, Coronavirus disease 2019; CPK, creatine phosphokinase; LDH, lactate dehydrogenase; RTI, respiratory

Day One Biopharmaceuticals — Q3 2024 Earnings Presentation on 6ix